329 related articles for article (PubMed ID: 35563051)
21. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.
Moussay E; Palissot V; Vallar L; Poirel HA; Wenner T; El Khoury V; Aouali N; Van Moer K; Leners B; Bernardin F; Muller A; Cornillet-Lefebvre P; Delmer A; Duhem C; Ries F; van Dyck E; Berchem G
Mol Cancer; 2010 May; 9():115. PubMed ID: 20487546
[TBL] [Abstract][Full Text] [Related]
22. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.
Ferracin M; Zagatti B; Rizzotto L; Cavazzini F; Veronese A; Ciccone M; Saccenti E; Lupini L; Grilli A; De Angeli C; Negrini M; Cuneo A
Mol Cancer; 2010 May; 9():123. PubMed ID: 20504344
[TBL] [Abstract][Full Text] [Related]
23. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A
Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949
[TBL] [Abstract][Full Text] [Related]
24. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Farooqui MZ; Valdez J; Martyr S; Aue G; Saba N; Niemann CU; Herman SE; Tian X; Marti G; Soto S; Hughes TE; Jones J; Lipsky A; Pittaluga S; Stetler-Stevenson M; Yuan C; Lee YS; Pedersen LB; Geisler CH; Calvo KR; Arthur DC; Maric I; Childs R; Young NS; Wiestner A
Lancet Oncol; 2015 Feb; 16(2):169-76. PubMed ID: 25555420
[TBL] [Abstract][Full Text] [Related]
25. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.
Michels N; Boer JM; Enshaei A; Sutton R; Heyman M; Ebert S; Fiocco M; de Groot-Kruseman HA; van der Velden VHJ; Barbany G; Escherich G; Vora A; Trahair T; Dalla-Pozza L; Pieters R; Zur Stadt U; Schmiegelow K; Moorman AV; Zwaan CM; den Boer ML
Lancet Haematol; 2021 Oct; 8(10):e700-e710. PubMed ID: 34560013
[TBL] [Abstract][Full Text] [Related]
26. Immunophenotyping as a guide for targeted therapy.
Sonneveld P; Pieters R
Best Pract Res Clin Haematol; 2003 Dec; 16(4):629-44. PubMed ID: 14592647
[TBL] [Abstract][Full Text] [Related]
27. State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia.
Mirzaei H; Fathullahzadeh S; Khanmohammadi R; Darijani M; Momeni F; Masoudifar A; Goodarzi M; Mardanshah O; Stenvang J; Jaafari MR; Mirzaei HR
J Cell Physiol; 2018 Feb; 233(2):888-900. PubMed ID: 28084621
[TBL] [Abstract][Full Text] [Related]
28. The Role of miRNAs in Childhood Acute Lymphoblastic Leukemia Relapse and the Associated Molecular Mechanisms.
Barrios-Palacios D; Organista-Nava J; Balandrán JC; Alarcón-Romero LDC; Zubillaga-Guerrero MI; Illades-Aguiar B; Rivas-Alarcón AA; Diaz-Lucas JJ; Gómez-Gómez Y; Leyva-Vázquez MA
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203290
[TBL] [Abstract][Full Text] [Related]
29. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
30. NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions.
Mansouri L; Papakonstantinou N; Ntoufa S; Stamatopoulos K; Rosenquist R
Semin Cancer Biol; 2016 Aug; 39():40-8. PubMed ID: 27491692
[TBL] [Abstract][Full Text] [Related]
31. miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.
Sharma S; Pavlasova GM; Seda V; Cerna KA; Vojackova E; Filip D; Ondrisova L; Sandova V; Kostalova L; Zeni PF; Borsky M; Oppelt J; Liskova K; Kren L; Janikova A; Pospisilova S; Fernandes SM; Shehata M; Rassenti LZ; Jaeger U; Doubek M; Davids MS; Brown JR; Mayer J; Kipps TJ; Mraz M
Blood; 2021 May; 137(18):2481-2494. PubMed ID: 33171493
[TBL] [Abstract][Full Text] [Related]
32. The effects of microRNAs on glucocorticoid responsiveness.
Wang H; Gou X; Jiang T; Ouyang J
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1005-1011. PubMed ID: 28286901
[TBL] [Abstract][Full Text] [Related]
33. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.
Schriever F; Huhn D
Drugs; 2003; 63(10):953-69. PubMed ID: 12699399
[TBL] [Abstract][Full Text] [Related]
34. miR-324-3p and miR-508-5p expression levels could serve as potential diagnostic and multidrug-resistant biomarkers in childhood acute lymphoblastic leukemia.
Zamani A; Fattahi Dolatabadi N; Houshmand M; Nabavizadeh N
Leuk Res; 2021 Oct; 109():106643. PubMed ID: 34147937
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of MiR-15a and MiR-16-1 as prognostic biomarkers in chronic lymphocytic leukemia.
Braga TV; Evangelista FCG; Gomes LC; Araújo SSDS; Carvalho MDG; Sabino AP
Biomed Pharmacother; 2017 Aug; 92():864-869. PubMed ID: 28599250
[TBL] [Abstract][Full Text] [Related]
36. Aberrant expression profile of miR-32, miR-98 and miR-374 in chronic lymphocytic leukemia.
Rahimi Z; Ghorbani Z; Motamed H; Jalilian N
Leuk Res; 2021 Dec; 111():106691. PubMed ID: 34455196
[TBL] [Abstract][Full Text] [Related]
37. Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukaemia.
Chen R; Plunkett W
Best Pract Res Clin Haematol; 2010 Mar; 23(1):155-66. PubMed ID: 20620979
[TBL] [Abstract][Full Text] [Related]
38. Roles and clinical implications of microRNAs in acute lymphoblastic leukemia.
Ultimo S; Martelli AM; Zauli G; Vitale M; Calin GA; Neri LM
J Cell Physiol; 2018 Aug; 233(8):5642-5654. PubMed ID: 29154447
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-326 and microRNA-200c: Two novel biomarkers for diagnosis and prognosis of pediatric acute lymphoblastic leukemia.
Ghodousi ES; Rahgozar S
J Cell Biochem; 2018 Jul; 119(7):6024-6032. PubMed ID: 29630744
[TBL] [Abstract][Full Text] [Related]
40. Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia.
Humphries LA; Godbersen JC; Danilova OV; Kaur P; Christensen BC; Danilov AV
Br J Haematol; 2013 Dec; 163(5):590-602. PubMed ID: 24117128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
